Answers are grounded in this paper and cite their sources.
Evaluates antioxidant and AChE inhibitory properties in Pelargonium endlicherianum extracts, indicating therapeutic potential for neurodegenerative disorders.
Pelargonium endlicherianum Fenzl, a perennial shrub in the Geraniaceae family, holds ethnobotanical importance. This study is the first to evaluate the acetylcholinesterase (AChE) and paraoxonase (hPON1) inhibitory activities, alongside the antioxidant properties, of P. endlicherianum extracts. Using LC-MS/MS, 25 phenolic compounds were quantified, with ellagic acid (20,449.65 ± 0.60 mg/kg), gallic acid (9,700.31 ± 0.03 mg/kg), and fumaric acid (1,691.34 ± 33.34 mg/kg) as the dominant bioactive components. Antioxidant assays (DPPH•, ABTS•+, FRAP, and CUPRAC) demonstrated that the ultrapure water extract exhibited superior activity, with a DPPH• scavenging capacity of 75.06 ± 0.73% at 0.2 mg/mL. The ultrapure water extract significantly inhibited AChE with an IC₅₀ value of 0.135 ± 0.29 mg/mL, while no inhibition of hPON1 was observed, indicating an anti-atherogenic effect. Molecular docking analysis revealed ellagic acid as the most potent compound, with a binding affinity of -10.0 kcal/mol, outperforming the reference inhibitor tacrine (-8.6 kcal/mol). Gene network analysis supported the involvement of ellagic acid , gallic acid , and fumaric acid in Alzheimer's disease-related pathways. These findings suggest that P. endlicherianum extracts possess significant antioxidant and AChE inhibitory properties, making them promising candidates for therapeutic applications, particularly in neurodegenerative disorders.
No takes yet. Share an insight, caveat, or question.
Güzel et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: